Navigation Links
Clarient Joins the HistoRx® Clinical Trials Network: First Commercial Lab to Provide Aqua® Technology for Clinical Trials
Date:10/24/2011

BRANFORD, Conn., Oct. 24, 2011 /PRNewswire/ -- Clarient, a GE Healthcare company, and HistoRx® , Inc., have signed a definitive agreement to provide pharma services using AQUA® technology to their growing lists of pharma clients.  By implementing HistoRx's AQUA technology in Clarient's CLIA laboratory, the two companies will apply their complementary capabilities to serve pharma companies' growing need for biomarker analysis in clinical trials. Use of tissue biomarkers to characterize a patient's tumor is becoming a crucial element of personalized cancer care.  AQUA technology is an automated, quantitative IHC testing method that enables standardized precision measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.

"HistoRx has helped numerous pharma clients with key development-phase decisions in the preclinical and translational medicine areas, harnessing the power of protein biomarkers to advance drug development," said Dick Carroll, Ph.D., Vice President of Clinical Research. "Now that AQUA technology is sought by drug developers for clinical trial support, raising the prospect of launching companion diagnostics based on these studies, expanding the network to include a commercial lab like Clarient gives more choices to study sponsors."

AQUA technology is increasingly used for high-precision evaluation of tissue biomarkers to formulate and test clinical hypotheses, particularly those centered on providing robust patient selection criteria for a given therapeutic in clinical trials.  The HistoRx Clinical Trials Network (HCTN) was initiated in response to significant interest from clinical research sponsors to have AQUA technology services available in a CLIA lab setting; HCTN members are the only sites approved and certified to perform AQUA analysis supporting clinical trials.  For the past five years pharmaceutical companies and oncology cooperative groups, and the researchers and clinicians involved in drug discovery, preclinical research and clinical development at those institutions, have used HistoRx Pharma Services to generate crucial information about their drug candidates, the metabolic pathways they affect, and the patient subgroups most likely to benefit from them.  The insights generated through AQUA technology and HistoRx Pharma Services provide compelling results with clear value in clinical programs, enabling pharmaceutical and biotech companies to use them for prospective analysis of patients in late-stage trials.  The HCTN, though centered on AQUA technology, has expanded its menu of offerings to include additional analysis technologies for use in clinical trials.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care and is the leader in quantitative immunohistochemistry.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA technology.  AQUA technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision making and patient outcomes in cancer care.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
2. Clarient Acquires Applied Genomics, Inc.
3. Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
4. Clarient Announces CFO Transition Plan
5. GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.
6. Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test
7. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
8. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
9. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
10. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
11. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... Global Ampoules Market report provides ... applications and industry chain structure. The Ampoules market analysis ... competitive landscape analysis, and major regions, development status. ... ... providing 10 company profiles and 183 tables and figures ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter ... demand for the product – with nearly 2,000 consumers (and counting) already backing ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, ... pleased to announce Westchester resident Lauren C. Enea has joined the firm as an ... will concentrate her practice in elder law, Medicaid planning and applications, and Wills, Trusts ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, ... Master in Frederick, MD. Judy says, “I am passionate about sharing Reiki as ... a very difficult and challenging time.” , A Certified Medical Reiki™ Master trained ...
(Date:3/24/2017)... ... 24, 2017 , ... “The Communion of Saints: A Pastor’s ... in congregations across the United States. “The Communion of Saints” is the ... has served congregations in seven states throughout his long career of devotion to ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center ... Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite ... This newest location will provide patients living in the north Houston area (The Woodlands, ...
Breaking Medicine News(10 mins):